secwatch / observer
CRMD CorMedix Inc.
CIK 0001410098 50 ready 8-Ks latest November 10, 2026, 5:15 PM ET RSS · JSON
Activity: ELEVATED 4 filings / 30d vs 1 baseline
Ready 8-Ks 50
Latest filing November 10, 2026, 5:15 PM ET
Top materiality 0.95
Event mix earnings ×20 · other_material ×8 · regulatory ×7
Sentiment 29 pos · 2 neg · 19 neu
Latest earnings ▲ beat 2025-FY
Executive change recent →

Recent 8-K filings for CRMD

Highest-materiality recent filing

CorMedix announces FDA approval of DefenCath to reduce catheter-related bloodstream infections in hemodialysis patients

November 16, 2023, 6:59 PM ET regulatory materiality 0.95 positive item 8.01item 9.01

Read filing →

Executive changes

Departed

Phoebe Mounts

Executive Vice President, General Counsel and Corporate Secretary
CRMD · CorMedix Inc.
Effective
2023-12-31
Filed
December 15, 2023, 6:59 PM ET
On December 12, 2023, upon mutual agreement between CorMedix Inc. (the “Company”) and Phoebe Mounts, Ph.D., Esq., the Company’s Executive Vice President, General Counsel and Corporate Secretary, the Board of Directors of the Company (the “Board”) approved the separation of employment of Dr. Mounts, effective December 31, 2023
Departed

Paulo F. Costa

Member of the Board of Directors
CRMD · CorMedix Inc.
Effective
2023-10-15
Filed
August 17, 2023, 7:59 PM ET
On August 14, 2023, Paulo F. Costa, a member of the Board of Directors (the “Board”) of CorMedix Inc. (the “Company”), notified the Board that he will be retiring from the Board, effective as of October 15, 2023.
Appointed

Robert Stewart

Director
CRMD · CorMedix Inc.
Effective
2023-04-13
Filed
April 17, 2023, 7:59 PM ET
On April 13, 2023, the Board of Directors (the “Board”) of CorMedix Inc. (the “Company”) appointed Robert Stewart as a director, effective immediately
Appointed

Joseph Todisco

Chief Executive Officer
CRMD · CorMedix Inc.
Filed
March 21, 2022, 7:59 PM ET
appointed Joseph Todisco as the Chief Executive Officer, commencing on such date as mutually agreed by Mr. Todisco and the Board, but in no event later than May 16, 2022.
Appointed

Joseph Todisco

Director
CRMD · CorMedix Inc.
Effective
2022-03-18
Filed
March 21, 2022, 7:59 PM ET
Mr. Todisco was appointed to serve as a member of the Board on March 18, 2022.
Role change

Matthew T. David

Chief Financial Officer
CRMD · CorMedix Inc.
Successor
Joseph Todisco
Filed
March 21, 2022, 7:59 PM ET
Dr. Matthew T. David will continue to serve as Interim Chief Executive Officer and Chief Financial Officer until Mr. Todisco commences employment, after which Dr. David will continue to serve as our Chief Financial Officer.
Role change (interim)

Matt David

interim Chief Executive Officer
CRMD · CorMedix Inc.
Effective
2021-10-26
Filed
October 29, 2021, 7:59 PM ET
On October 26, 2021, CorMedix Inc. (“Company”) and Matt David, M.D., the Company’s current Chief Financial Officer, entered into a letter agreement (the “Letter Agreement”) modifying certain terms of his employment agreement with the Company, dated May 11, 2020 (“Employment Agreement”), and providing other compensation, as a result of Dr. David serving as interim Chief Executive Officer of the Company.
Appointed (interim)

Matthew David

Interim Chief Executive Officer
CRMD · CorMedix Inc.
Effective
2021-10-04
Filed
October 5, 2021, 7:59 PM ET
Matthew David, M.D., the Company’s current Chief Financial Officer, will serve as interim Chief Executive Officer, effective immediately, until a new Chief Executive Officer is appointed.
Departed

John L. Armstrong, Jr.

Executive Vice President, Technical Operations
CRMD · CorMedix Inc.
Effective
2021-10-04
Filed
October 5, 2021, 7:59 PM ET
On October 4, 2021, the Company and John L. Armstrong, Jr. came to a mutual agreement pursuant to which Mr. Armstrong will retire from his position as the Company’s Executive Vice President, Technical Operations, effective October 4, 2021.
Departed (interim)

Khoso Baluch

Chief Executive Officer
CRMD · CorMedix Inc.
Effective
2021-10-04
Successor
Matthew David
Filed
October 5, 2021, 7:59 PM ET
On October 1, 2021, the Company and Khoso Baluch came to a mutual agreement pursuant to which Mr. Baluch will retire from his position as the Company’s Chief Executive Officer, effective October 4, 2021.

Earnings & guidance

2025-FY EPS reported $2.04 vs consensus $0.83 ▲ beat (+145.0%) filing →

Materiality & sentiment trend

Max materiality 0.95 · Median 0.70 · Most common event earnings

29 positive 2 negative 19 neutral

source · CRMD on sec.gov